Skip to content

Seegene and Hologic Form Worldwide Collaboration to Develop High Multiplex Molecular Diagnostic Assays

Published on: PR Newswire GenomeWeb

Seoul, Korea, November 4, 2016 —  Seegene Inc. (096530.KQ) today announced it has entered into a worldwide collaboration agreement with Hologic (Nasdaq: HOLX) to develop and supply high multiplex real-time PCR reagents for the Hologic Panther Fusion™ system that is currently in development. 

Under the terms of the agreement, Seegene will develop and manufacture multiplex assays based on DPO™, TOCE™, and MuDT™ technologies for Hologic’s next generation molecular diagnostics platform, the Panther Fusion™ system. Hologic, in turn, will obtain worldwide commercialization rights to these assays. Financial terms of the agreement were not disclosed. 

Hologic is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with strong positions in women’s health. Hologic’s Panther® system is a fully automated sample-to-answer instrument, which eliminates the need for batch processing and automates all aspects of nucleic acid testing on a single, integrated platform. The Fusion expansion module, once commercialized, will provide laboratory customers a seamless evolution of their Panther system and allow expanded assay menu with real-time PCR capabilities in a single-unit-dose format. 

Hologic Diagnostic President Tom West said, “We are pleased to partner with Seegene and incorporate their innovative technologies with our system. Seegene’s multiplex reagents will enable simultaneous detection and quantification of various target genes, further broadening the menu of Hologic’s Panther Fusion™ system and strengthening its leadership position in the molecular diagnostic market.” 

Seegene expands tremendous effort to continually develop and commercialize innovative high multiplex PCR technologies that enable more accurate and cost-effective molecular diagnostics. MuDT™ technology provides perfection of qPCR technology by simultaneously identifying and quantifying multiple targets in a single fluorescence channel. 

Dr. Jong-Yoon Chun, Founder and CEO of Seegene said, “Our agreement with Hologic represents another meaningful milestone to Seegene’s global expansion initiatives in the molecular diagnostics market. We expect to accelerate technological standardization in the MDx market by building up capabilities of assay development applying on various platforms.” 

About Seegene
Seegene is the world’s leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene’s core enabling technologies ? DPO™, TOCE™, and MuDT™ – are the foundation for M-MoDx tests that can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility.  Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene’s mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies. For more information, please visit

Back To Top